Claims for Patent: 9,951,010

Summary for Patent: 9,951,010

Title:	Compounds as CRTH2 antagonist and uses thereof
Abstract:	The compounds of Formula (I) which can be used as CRTH2 receptor antagonists are provided. The compounds of Formula (I) can be used in the treatment and prevention of asthma, allergic rhinitis and atopic dermatitis, as well as other diseases mediated by prostaglandin D2 (PGD2) at the CRTH2 receptor. ##STR00001##
Inventor(s):	Zhang; Yingjun (Dongguan, CN), Yu; Tianzhu (Dongguan, CN), Liu; Bing (Dongguan, CN), Zhang; Xiangyu (Dongguan, CN), Zhang; Shiguo (Dongguan, CN), Cheng; Changchung (Dongguan, CN), Zhang; Jiancun (Dongguan, CN)
Assignee:	SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN)
Application Number:	15/504,018
Patent Claims:	1. A compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, or a pharmaceutically acceptable salt thereof, ##STR00130## wherein A is 6- to 9-membered heterocyclylene, 4-membered heterocyclylene, spiro heterobicyclylene, fused heterobicyclylene, bridged heterobicyclylene, spiro bicyclylene, fused bicyclylene, bridged bicyclylene, cycloalkylene, heteroarylene or arylene; A is optionally substituted with 1, 2, 3 or 4 independent R.sup.2; E is C.sub.3-6 heterocyclyl, cycloalkyl, spiro heterobicyclyl, fused heterobicyclyl, bridged heterobicyclyl, C.sub.6-12 aryl or C.sub.1-9 heteroaryl; E is optionally substituted with 1, 2, 3 or 4 independent R.sup.2c; L.sup.1 is --O--, --S(.dbd.O).sub.t--, --S--, --N(R.sup.1)--, --CH.sub.2--, --CH(OH)--, --C(.dbd.O)O--, --N(R.sup.1)--C(.dbd.O)--, --C(.dbd.O)--(CH.sub.2).sub.n--, --C(.dbd.O)--, --OC(.dbd.O)--, --C(.dbd.S)--, --C(.dbd.O)--N(R.sup.1)--, --C(.dbd.S)--N(R.sup.1)-- or --(CH.sub.2).sub.n--C(.dbd.O)--; each L.sup.2 is independently a bond, --O--, --S(.dbd.O).sub.t--, --S--, --N(R.sup.1)--, --C(.dbd.O)O--, --N(R.sup.1)--C(.dbd.O)--, --C(.dbd.O)--(CH.sub.2).sub.n--, --CH.sub.2--, --C(.dbd.O)--, --OC(.dbd.O)--, --C(.dbd.S)--, --C(.dbd.O)--N(R.sup.1)--, --C(.dbd.S)--N(R.sup.1)-- or --(CH.sub.2).sub.n--C(.dbd.O)--; w is 0, 1, 2, 3 or 4; each n is independently 0, 1, 2, 3 or 4; each t is independently 0, 1 or 2; each R.sup.1a and R.sup.1 is independently H, C.sub.1-4 alkyl, halo-C.sub.1-4-alkyl, C.sub.1-4alkylacyl or hydroxy; each R.sup.2c and R.sup.2 is independently H, C.sub.1-4alkyl, C.sub.1-4 haloalkyl, hydroxy, nitro, amino, cyano, halogen, carboxy, C.sub.1-4 alkoxy, C.sub.1-4 alkylamino, C.sub.1-4 alkylthio, C.sub.1-4 alkylacyl, C.sub.3-12 cycloalkyl, C.sub.3-9 heterocyclyl, C.sub.6-12 aryl, C.sub.1-9 heteroaryl, amino-C.sub.1-4-alkyl, hydroxy-C.sub.1-4-alkyl, sulfo, R.sup.2b-L-, aminosulfonyl or aminoacyl; each L is independently --O--, --S(.dbd.O).sub.t--, --S--, --N(R.sup.1a)--, --CH.sub.2--, --C(.dbd.O)--, --OC(.dbd.O)--, --C(.dbd.S)--, --C(.dbd.O)--N(R.sup.1a)--, --C(.dbd.S)--N(R.sup.1a)-- or --(CH.sub.2).sub.n--C(.dbd.O)--; and each R.sup.2b is independently H, C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, C.sub.3-9 cycloalkyl, C.sub.3-6 heterocyclyl, C.sub.6-12 aryl, C.sub.1-9 heteroaryl, amino-C.sub.1-4-alkyl, amino or hydroxy-C.sub.1-4-alkyl. 2. The compound of claim 1, wherein A is 6- to 9-membered heterocyclylene, 4-membered heterocyclylene, C.sub.5-12 spiro heterobicyclylene, C.sub.5-12 fused heterobicyclylene, C.sub.5-12 bridged heterobicyclylene, C.sub.5-12 spiro bicyclylene, C.sub.5-12 fused bicyclylene, C.sub.5-12 bridged bicyclylene, C.sub.3-12 cycloalkylene, C.sub.1-9 heteroarylene or C.sub.6-12 arylene; and each of 6- to 9-membered heterocyclylene, 4-membered heterocyclylene, C.sub.5-12 spiro bicyclylene, C.sub.5-12 fused bicyclylene, C.sub.5-12 bridged bicyclylene, C.sub.5-12 spiro heterobicyclylene, C.sub.5-12 fused heterobicyclylene, C.sub.5-12 bridged heterobicyclylene, C.sub.3-12 cycloalkylene, C.sub.1-9 heteroarylene and C.sub.6-12 arylene is optionally and independently substituted with 1, 2, 3 or 4 independent R.sup.2; or A is one of the following sub-structures: ##STR00131## wherein when X.sup.2a is a single bond, ##STR00132## when X.sup.2a is a double bond ##STR00133## each X.sup.1, X.sup.2, T.sup.1 and X.sup.3 is independently --(CR.sup.3R.sup.3a).sub.b--, --O--, --N(R.sup.4)-- or --S--; each X.sup.4, X.sup.5, X.sup.6, X.sup.7, X.sup.8, X.sup.9 and X is independently C(R.sup.3) or N; each b is independently 1, 2, 3 or 4; each q, m, p and r is independently 0, 1, 2, 3 or 4; each R.sup.3 and R.sup.3a is independently H, C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, hydroxy, nitro, cyano, halogen, amino, carboxy, C.sub.1-4 alkoxy, C.sub.1-4 alkylamino, C.sub.1-4 alkylthio, C.sub.1-4 alkylacyl, C.sub.3-12 cycloalkyl, C.sub.3-9 heterocyclyl, C.sub.6-12 aryl, C.sub.1-9 heteroaryl, amino-C.sub.1-4-alkyl, hydroxy-C.sub.1-4-alkyl, sulfo, aminosulfonyl or aminoacyl; each R.sup.4 is independently H, C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, hydroxy, C.sub.3-12 cycloalkyl, C.sub.3-9 heterocyclyl, C.sub.6-12 aryl, C.sub.1-9 heteroaryl, amino-C.sub.1-4-alkyl or hydroxy-C.sub.1-4-alkyl; and each moiety represented by A is optionally and independently substituted with 1, 2, 3 or 4 independent R.sup.2. 3. The compound of claim 1, wherein A is ##STR00134## each moiety represented by A is optionally and independently substituted with 1, 2, 3 or 4 independent R.sup.2. 4. The compound of claim 1, wherein E is C.sub.1-9 heterocyclyl, C.sub.5-12spiro heterobicyclyl, C.sub.5-12fused heterobicyclyl, C.sub.5-12bridged heterobicyclyl, C.sub.3-12cycloalkyl, C.sub.6-12 aryl or C.sub.1-12 heteroaryl; and each of C.sub.1-9 heterocyclyl, C.sub.5-12spiro heterobicyclyl, C.sub.5-12fused heterobicyclyl, C.sub.5-12bridged heterobicyclyl, C.sub.3-12cycloalkyl, C.sub.6-12 aryl and C.sub.1-12 heteroaryl is optionally and independently substituted with 1, 2, 3 or 4 independent R.sup.2c; or E is one of the following monovalent groups: ##STR00135## wherein each Y, Y.sup.1, Y.sup.2, Y.sup.3, Y.sup.4, Y.sup.5 and Y.sup.6 is independently N or CH; each T is independently --O--, --S--, --NH-- or --CH.sub.2--; and each of the monovalent groups is optionally and independently substituted with 1, 2, 3 or 4 independent R.sup.2c. 5. The compound of claim 1 having Formula (II) or a stereoisomer, a geometric isomer, a tautomer, or a pharmaceutically acceptable salt thereof, ##STR00136## wherein when X.sup.2a is a single bond, ##STR00137## when X.sup.2a is a double bond, ##STR00138## each X.sup.1, X.sup.2 and X.sup.3 is independently --(CR.sup.3R.sup.3a).sub.b--, --O--, --N(R.sup.4)-- or --S--; each X.sup.4 is independently C(R.sup.3) or N; each b is independently 1, 2, 3 or 4; each R.sup.3 and R.sup.3a is independently H, C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, hydroxy, nitro, cyano, halogen, amino, carboxy, C.sub.1-4 alkoxy, C.sub.1-4 alkylamino, C.sub.1-4 alkylthio, C.sub.1-4 alkylacyl, C.sub.3-12 cycloalkyl, C.sub.3-9 heterocyclyl, C.sub.6-12 aryl, C.sub.1-9 heteroaryl, amino-C.sub.1-4-alkyl, hydroxy-C.sub.1-4-alkyl, sulfo, aminosulfonyl or aminoacyl; and each R.sup.4 is independently H, C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, hydroxy, C.sub.3-12 cycloalkyl, C.sub.3-9 heterocyclyl, C.sub.6-12 aryl, C.sub.1-9 heteroaryl, amino-C.sub.1-4-alkyl or hydroxy-C.sub.1-4-alkyl. 6. The compound of claim 1 having Formula (IIa) or a stereoisomer, a geometric isomer, a tautomer, or a pharmaceutically acceptable salt thereof, ##STR00139## 7. The compound of claim 1, wherein E is one of the following C.sub.6-12 aryl and C.sub.1-9 heteroaryl groups: ##STR00140## each moiety represented by E is optionally and independently substituted with 1, 2, 3 or 4 independent R.sup.2c. 8. The compound of claim 1, wherein each R.sup.2c and R.sup.2 is independently H, methyl, ethyl, n-propyl, isopropyl, t-butyl, n-butyl, trifluoromethyl, hydroxy, nitro, amino, cyano, F, Cl, Br, carboxy, methoxy, ethoxy, isopropoxy, methylamino, ethylamino, dimethylamino, methylacyl, aminomethyl, hydroxymethyl, sulfo, R.sup.2b-L-, aminosulfonyl or aminoacyl; and each R.sup.2b is independently H, methyl, ethyl, n-propyl, isopropyl, n-butyl, trifluoromethyl, cyclopentyl, cyclohexyl, cyclobutyl, morpholinyl, piperidyl, pyrrolyl, hydroxymethyl or amino. 9. The compound of claim 1, wherein the pharmaceutically acceptable salt is an inorganic acid salt, organic acid salt, inorganic base salt, alkali metal salt or organic base salt. 10. The compound of claim 9, wherein the pharmaceutically acceptable salt is hydrochloride, hydrobromide, hydriodate, nitrate, sulfate, disulfate, phosphate, acetate, propionate, butyrate, lactate, mesylate, tosilate, maleate, benzoate, succinate, tartrate, citrate, oxalate, fumarate, taurinate, sodium salt, potassium salt or ammonium salt. 11. The compound of claim 1 having one of the following structures or a stereoisomer, a geometric isomer, a tautomer, or a pharmaceutically acceptable salt thereof: ##STR00141## ##STR00142## ##STR00143## ##STR00144## ##STR00145## ##STR00146## ##STR00147## ##STR00148## ##STR00149## ##STR00150## ##STR00151## ##STR00152## ##STR00153## ##STR00154## ##STR00155## ##STR00156## ##STR00157## ##STR00158## ##STR00159## ##STR00160## ##STR00161## ##STR00162## ##STR00163## ##STR00164## ##STR00165## ##STR00166## ##STR00167## ##STR00168## ##STR00169## 12. A crystalline form of 2-(5-fluoro-3-(1-((4-fluorophenyl)sulfonyl)piperidin-4-yl)-2-methyl-1H-in- dol-1-yl)acetic acid (Formula VI), wherein the crystalline form is crystalline form I, crystalline form II, crystalline form III, crystalline form IV, crystalline form V or crystalline form VI: ##STR00170## wherein: crystalline form I has an X-ray powder diffraction (XRPD) pattern comprising peaks expressed in degrees 2.theta. at 3.80.degree., 13.20.degree., 15.46.degree., 17.24.degree., 18.90.degree., 19.27.degree., 19.57.degree., 23.84.degree. and 28.39.degree., where the error margin is .+-.0.2.degree.; crystalline form II has an X-ray powder diffraction (XRPD) pattern comprising peaks expressed in degrees 2.theta. at 5.96.degree., 12.09.degree., 13.17.degree., 14.14.degree., 15.96.degree., 16.85.degree., 17.97.degree., 20.77.degree., 24.07.degree., 24.64.degree. and 28.99.degree., where the error margin is .+-.0.2.degree.; crystalline form III has an X-ray powder diffraction (XRPD) pattern comprising peaks expressed in degrees 2.theta. at 15.67.degree., 16.20.degree., 18.28.degree., 20.02.degree., 20.89.degree., 23.28.degree. and 24.62.degree., where the error margin is .+-.0.2.degree.; crystalline form IV has an X-ray powder diffraction (XRPD) pattern comprising peaks expressed in degrees 2.theta. at 16.09.degree., 18.19.degree., 20.57.degree., 20.98.degree., 24.11.degree., 24.82.degree. and 25.93.degree., where the error margin is .+-.0.2.degree.; crystalline form V has an X-ray powder diffraction (XRPD) pattern comprising peaks expressed in degrees 2.theta. at 5.88.degree., 12.86.degree., 15.68.degree., 17.69.degree., 20.50.degree., 23.60.degree. and 24.17.degree., where the error margin is .+-.0.2.degree.; and crystalline form VI has an X-ray powder diffraction (XRPD) pattern comprising peaks expressed in degrees 2.theta. at 5.84.degree., 12.83.degree., 13.20.degree., 15.72.degree., 17.63.degree., 23.62.degree. and 28.94.degree., where the error margin is .+-.0.2.degree.. 13. A pharmaceutical composition comprising the compound of claim 1; and at least one of pharmaceutically acceptable carriers, excipients, diluents, adjuvants and vehicles. 14. The pharmaceutical composition of claim 13 further comprising one or more other active agents, wherein the other active agent is salmeterol, fluticasone, loratadine, montelukast, omalizumab, fusidic acid, clotrimazole, tacrolimus, pimecrolimus, DP antagonist, cilomilast, TNF-.alpha. converting enzyme (TACE) inhibitor, blocking monoclonal antibody or soluble receptor of IL-4 and IL-5 or zileuton. 15. A method of treating a disease mediated by PGD.sub.2 at the CRTH2 receptor in a patient comprising administering the compound of claim 1 to the patient, wherein the disease mediated by PGD.sub.2 at the CRTH2 receptor is asthma, COPD, allergic asthma, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity, conjunctivitis, eosinophilic bronchitis, food allergies, eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, and mastocytosis. 16. A method of treating a disease mediated by PGD.sub.2 at the CRTH2 receptor in a patient comprising administering the pharmaceutical composition of claim 13 to the patient, wherein the disease mediated by PGD.sub.2 at the CRTH2 receptor is asthma, COPD, allergic asthma, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity, conjunctivitis, eosinophilic bronchitis, food allergies, eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, and mastocytosis.

Details for Patent 9,951,010

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	XOLAIR	omalizumab	For Injection	103976	06/20/2003		2034-09-13
Genentech, Inc.	XOLAIR	omalizumab	Injection	103976	09/28/2018		2034-09-13